References
- Fuhlbrigge A, Peden A, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol 2012;129(3 Suppl):S34-48
- Global strategy for asthma management and prevention. Revised 2014. Global Initiative for Asthma. Available at: http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_August 12.pdf [Last accessed 21 December 2014]
- Graham LM, Eid N. The impact of asthma exacerbations and preventive strategies. Curr Med Res Opin 2015 Feb 9. [Epub ahead of print]. doi:10.1185/03007995.2014.1001062
- Sheikh A, Hurwitz B, Nurmatov U, et al. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev 2010;7:CD001563
- Incorvaia C, Mauro M, Russello M, et al. Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Des Devel Ther 2014;8:197-207
- Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010;8:CD001186
- Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558-62
- Canonica GW, Bousquet J, Casale T. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64(Suppl 91):1-59
- Ridolo E, Montagni M, Bonzano L, et al. Arguing the misconceptions in allergen-specific immunotherapy. Immunotherapy 2014;6:587-95
- Hamelmann E, Rolinck-Werninghaus C, Wahn U. Is there a role for anti-IgE in combination with specific allergen immunotherapy? Curr Opin Allergy Clin Immunol 2003;3:501-10
- Lambert N, Guiddir T, Amat F, Just J. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol 2014;25:829–32
- Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-31
- Ciprandi G, Incorvaia C, Puccinelli P, et al. Polysensitization as a challenge for the allergist: the suggestions provided by the Polysensitization Impact on Allergen Immunotherapy studies. Expert Opin Biol Ther 2011;11:715-22
- Ciprandi G, Cadario G, Valle C, et al. Sublingual immunotherapy in polysensitized patients: effect on quality of life. J Investig Allergol Clin Immunol 2010;20:274-9
- Blumberga G, Groes L, Haugard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006;61:843-8
- Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134:568-75
- Voltolini S, Troise C, Incorvaia C, et al. Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study. Curr Med Res Opin 2010;26:37-40
- Custovic A, Simpson A, Bardin PG, Le Souëf P. Allergy is an important factor in asthma exacerbation: a pro/con debate. Respirology 2010;15:1021-7
- Mendell M, Mirer A, Cheung K, et al. Respiratory and allergic health effects of dampness, mold, and dampness-related agents: a review of the epidemiologic evidence. Environ Health Perspect 2011;119:748-56
- Quansah R, Jaakkola MS, Hugg TT, et al. Residential dampness and molds and the risk of developing asthma: a systematic review and meta-analysis. PLoS One 2012;7:e47526
- Crameri R, Garbani M, Rhyner C, Huitema C. Fungi: the neglected allergenic sources. Allergy 2014;69:176-85
- Rank MA, Liesinger JT, Ziegenfuss JY, et al. The impact of asthma medication guidelines on asthma controller use and on asthma exacerbation rates comparing 1997–1998 and 2004–2005. Ann Allergy Asthma Immunol 2012;108:9-13